Other concerns have been raised regarding the negative effect of the program on the welfare of the Iranian populace. According to the Human Rights Watch, the redoubled U.S. sanctions has effectively constrained Iran's "ability to finance [...] humanitarian imports", due to the broad U.S. sanctions against Iranian banks, accompanied by the "aggressive rhetoric from U.S. officials". The intensified sanctions has seriously threatened Iranians' right to health and access to essential medicines, causing documented shortages—ranging from a lack of vital drugs for patients with epilepsy to limited chemotherapy medications for treating Iranian cancer patients.[6]